Patents by Inventor Thierry MONNEY

Thierry MONNEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD3/BCMA/CD38 trispecific antibodies
    Patent number: 12692314
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Grant
    Filed: May 4, 2023
    Date of Patent: July 28, 2026
    Assignee: IGI THERAPEUTICS SA
    Inventors: Maria Pihlgren Bosch, Mario Perro, Olivia Hall, Laura Carretero Iglesia, Adam Drake, Daniela Pais, Rebecca Croasdale-Wood, Carole Estoppey, Michael Dyson, Thierry Monney
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20260071000
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this 5 novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: May 16, 2025
    Publication date: March 12, 2026
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI
  • Antibodies that bind to IL1RAP and uses thereof
    Patent number: 12492259
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: December 9, 2025
    Assignee: IGI THERAPEUTICS SA
    Inventors: Julie Macoin, Amelie Croset, Jeremy Loyau, Thierry Monney, Lamine Mbow, Marie-Agnes Doucey, Valentina Labanca
  • Antibodies that bind to IL1RAP and uses thereof
    Patent number: 12492260
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: December 9, 2025
    Assignee: IGI THERAPEUTICS SA
    Inventors: Julie Macoin, Amelie Croset, Jeremy Loyau, Thierry Monney, Lamine Mbow, Marie-Agnes Doucey, Valentina Labanca
  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20250361310
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and may also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: June 4, 2025
    Publication date: November 27, 2025
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • AFFINITY MATURED ANTI-OX40 ANTIBODIES AND USE THEREOF
    Publication number: 20250353921
    Abstract: Provided herein are high affinity antagonistic anti-OX40 antibodies, methods of making such antibodies, and methods of using such antibodies to treat OX40-mediated disorders.
    Type: Application
    Filed: July 29, 2025
    Publication date: November 20, 2025
    Inventors: Julie Macoin, Thierry Monney, Nikolaos Biris, Jill C. Milne, Christopher J. Morabito, Chunxia Zhao
  • CD47-CD38 bispecific antibodies
    Patent number: 12338292
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: June 24, 2025
    Assignee: IGI Therapeutics SA
    Inventors: Laure Bouchez, Blandine Pouleau, Marie-Agnes Doucey, Elie Dheilly, Stanislas Blein, Cian Stutz, Carole Estoppey, Jeremy Loyau, Thierry Monney, Camille Grandclement, Stefano Sammicheli
  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20240327530
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20240327531
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • CD3/BCMA/CD38 Trispecific Antibodies
    Publication number: 20240228650
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Application
    Filed: May 4, 2023
    Publication date: July 11, 2024
    Inventors: Maria PIHLGREN BOSCH, Mario PERRO, Olivia HALL, Laura CARRETERO IGLESIA, Adam DRAKE, Daniela PAIS, Rebecca CROASDALE-WOOD, Jérémy LOYAU, Carole ESTOPPEY, Ankita SRIVASTAVA, Michael DYSON, Julie MACOIN, Myriam CHIMEN, Thierry MONNEY, Cyrille DREYFUS
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20240150489
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: October 11, 2023
    Publication date: May 9, 2024
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20240141062
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: October 11, 2023
    Publication date: May 2, 2024
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI, Cyrille DREYFUS
  • Antibodies that bind to IL1RAP and uses thereof
    Patent number: 11970539
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and may also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: April 30, 2024
    Assignee: Ichnos Sciences SA
    Inventors: Julie Macoin, Amelie Croset, Jeremy Loyau, Thierry Monney, Lamine Mbow, Marie-Agnes Doucey, Valentina Labanca
  • CD3/BCMA/CD38 Trispecific Antibodies
    Publication number: 20240132615
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Application
    Filed: May 3, 2023
    Publication date: April 25, 2024
    Inventors: Maria PIHLGREN BOSCH, Mario PERRO, Olivia HALL, Laura CARRETERO IGLESIA, Adam DRAKE, Daniela PAIS, Rebecca CROASDALE-WOOD, Jérémy LOYAU, Carole ESTOPPEY, Ankita SRIVASTAVA, Michael DYSON, Julie MACOIN, Myriam CHIMEN, Thierry MONNEY, Cyrille DREYFUS
  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20220089754
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 24, 2022
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20220089767
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Laure Bouchez, Blandine Pouleau, Marie-Agnes Doucey, Elie Dheilly, Stanislas Blein, Cian Stutz, Carole Estoppey, Jeremy Loyau, Thierry Monney, Camille Grandclement, Stefano Sammicheli